PLCγ1‑dependent invasion and migration of cells expressing NSCLC‑associated EGFR mutants

Mittal,Sonam; Kamath,Arpana; Joseph,Ann  M.; Rajala,Maitreyi  S.

doi:10.3892/ijo.2020.5112

PLCγ1‑dependent invasion and migration of cells expressing NSCLC‑associated EGFR mutants

Authors:
- Sonam Mittal
- Arpana Kamath
- Ann M. Joseph
- Maitreyi S. Rajala
View Affiliations

Affiliations: School of Biotechnology, Jawaharlal Nehru University, New Delhi 110067, India, Department of Biochemistry, Amala Cancer Research Centre, Thrisuur, Kerala 680555, India
Published online on: August 19, 2020 https://doi.org/10.3892/ijo.2020.5112
Pages: 989-1000

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The increased tyrosine kinase activity of non‑small cell lung cancer (NSCLC)‑associated epidermal growth factor receptor (EGFR) mutants results in deregulated pathways that contribute to malignant cell survival, tumor progression and metastasis. Previous studies investigating lung cancer‑associated EGFR have focused on the prognostic implications of receptor kinase mutations in patients with NSCLC; however, the role of EGFR mutations in tumor cell invasion and migration remains undetermined. The present study was designed to investigate the role of NSCLC‑associated mutant EGFR‑driven signaling pathways in cell proliferation and invasion. Non‑endogenous EGFR‑expressing 293 cells stably expressing EGFR mutants that are sensitive or resistant to Food and Drug Administration (FDA)‑approved EGFR‑targeted tyrosine kinase inhibitors (TKIs) were used in the present study. The experiments demonstrated an increased phosphorylation of phospholipase (PLC)γ1, c‑Cbl, signal transducer and activator of transcription (Stat), extracellular regulated kinase (Erk)1/2, Akt, Shc and Gab1 proteins in cells expressing a mutant form, rather than the wild‑type receptor. As PLCγ1 is a known regulator of metastatic development, mutant receptor‑mediated PLCγ1 activation was further evaluated. To examine the effects of EGFR and PLCγ1 phosphorylation, the metastatic potential of cells expressing mutants was investigated using wound healing, Transwell cell migration and invasion assays. The inhibition of receptor phosphorylation with the 1st, 2nd and 3rd generation TKIs, gefitinib, afatinib, osimertinib, respectively, reduced PLCγ1 phosphorylation, and reduced the invasive and migratory potential of 293 cells, confirming PLCγ1 as one of the probable downstream effectors of mutant EGFR signaling. However, the PLC inhibitor, U73122, inhibited cell migration and invasion without affecting EGFR signaling and PLCγ1 phosphorylation. Notably, U73122 reduced Akt and Erk1/2 phosphorylation within 25 min of its application; however, 100% cell viability was recorded even after 48 h. Upon further investigation, proliferative signaling pathways remained active at 48 h, in accordance with cell viability. Therefore, the present study concludes that mutant receptor‑mediated PLCγ1 activation may play a significant role in the migration and invasion of NSCLC tumors; however, its regulatory role in tumor cell proliferation warrants further investigation and validation in lung tumor cell lines harboring EGFR mutations.

View Figures

View References

1	Chen Z, Fillmore CM, Hammerman PS, Kim CF and Wong K-K: Non-small-cell lung cancers: A heterogeneous set of diseases. Nat Rev Cancer. 14:535–546. 2014. View Article : Google Scholar : PubMed/NCBI
2	Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
3	Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
4	Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Jänne PA, Januario T, Johnson DH, et al: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 23:5900–5909. 2005. View Article : Google Scholar : PubMed/NCBI
5	Lièvre A, Bachet J-B, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, et al: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66:3992–3995. 2006. View Article : Google Scholar : PubMed/NCBI
6	Raymond E, Faivre S and Armand JP: Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs. 60(Suppl 1): 15–23; discussion 41–42. 2000. View Article : Google Scholar : PubMed/NCBI
7	Nguyen K-SH, Kobayashi S and Costa DB: Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer. 10:281–289. 2009. View Article : Google Scholar : PubMed/NCBI
8	Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos B: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
9	Oxnard GR, Arcila ME, Sima CS, Riely GJ, Chmielecki J, Kris MG, Pao W, Ladanyi M and Miller VA: Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: Distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res. 17:1616–1622. 2011. View Article : Google Scholar
10	Liao B-C, Lin C-C and Yang JC-H: Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol. 27:94–101. 2015. View Article : Google Scholar : PubMed/NCBI
11	Jänne PA, Yang JC-H, Kim D-W, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, et al: AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 372:1689–1699. 2015. View Article : Google Scholar : PubMed/NCBI
12	Cross DAE, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, et al: AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 4:1046–1061. 2014. View Article : Google Scholar : PubMed/NCBI
13	Sordella R, Bell DW, Haber DA and Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 305:1163–1167. 2004. View Article : Google Scholar : PubMed/NCBI
14	Kim Y, Apetri M, Luo B, Settleman JE and Anderson KS: Differential effects of tyrosine kinase inhibitors on normal and oncogenic EGFR signaling and downstream effectors. Mol Cancer Res. 13:765–774. 2015. View Article : Google Scholar : PubMed/NCBI
15	Kamath A, Joseph AM, Gupta K, Behera D, Jaiswal A, Dewan R and Rajala MS: Proteomic analysis of HEK293 cells expressing non small cell lung carcinoma associated epidermal growth factor receptor variants reveals induction of heat shock response. Exp Hematol Oncol. 4:162015. View Article : Google Scholar : PubMed/NCBI
16	Rasband WS: US National Institutes of Health, MD, USA. http://imagejnih.gov/ij/uri. 2011, Accessed August 28, 2008.
17	Piccolo E, Innominato PF, Mariggio MA, Maffucci T, Iacobelli S and Falasca M: The mechanism involved in the regulation of phospholipase Cgamma1 activity in cell migration. Oncogene. 21:6520–6529. 2002. View Article : Google Scholar : PubMed/NCBI
18	Wells A and Grandis JR: Phospholipase C-γ1 in tumor progression. Clin Exp Metastasis. 20:285–290. 2003. View Article : Google Scholar
19	Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, et al: BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 27:4702–4711. 2008. View Article : Google Scholar : PubMed/NCBI
20	Kobayashi Y and Mitsudomi T: Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy. Cancer Sci. 107:1179–1186. 2016. View Article : Google Scholar : PubMed/NCBI
21	Zhang F, Wang S, Yin L, Yang Y, Guan Y, Wang W, Xu H and Tao N: Quantification of epidermal growth factor receptor expression level and binding kinetics on cell surfaces by surface plasmon resonance imaging. Anal Chem. 87:9960–9965. 2015. View Article : Google Scholar : PubMed/NCBI
22	Yart A, Laffargue M, Mayeux P, Chretien S, Peres C, Tonks N, Roche S, Payrastre B, Chap H and Raynal P: A critical role for phosphoinositide 3-kinase upstream of Gab1 and SHP2 in the activation of ras and mitogen-activated protein kinases by epidermal growth factor. J Biol Chem. 276:8856–8864. 2001. View Article : Google Scholar : PubMed/NCBI
23	Hashimoto A, Kurosaki M, Gotoh N, Shibuya M and Kurosaki T: Shc regulates epidermal growth factor-induced activation of the JNK signaling pathway. J Biol Chem. 274:20139–20143. 1999. View Article : Google Scholar : PubMed/NCBI
24	Shtiegman K, Kochupurakkal BS, Zwang Y, Pines G, Starr A, Vexler A, Citri A, Katz M, Lavi S, Ben-Basat Y, et al: Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling. Oncogene. 26:6968–6978. 2007. View Article : Google Scholar : PubMed/NCBI
25	Nomoto K, Tomita N, Miyake M, Xhu DB, LoGerfo PR and Weinstein IB: Expression of phospholipases γ1, β1, and δ1 in primary human colon carcinomas and colon carcinoma cell lines. Mol Carcinog. 12:146–152. 1995. View Article : Google Scholar : PubMed/NCBI
26	Arteaga CL, Johnson MD, Todderud G, Coffey RJ, Carpenter G and Page DL: Elevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in primary human breast carcinomas. Proc Natl Acad Sci USA. 88:10435–10439. 1991. View Article : Google Scholar : PubMed/NCBI
27	Chen P, Xie H, Sekar MC, Gupta K and Wells A: Epidermal growth factor receptor-mediated cell motility: Phospholipase C activity is required, but mitogen-activated protein kinase activity is not sufficient for induced cell movement. J Cell Biol. 127:847–857. 1994. View Article : Google Scholar : PubMed/NCBI
28	Kundra V, Escobedo JA, Kazlauskas A, Kim HK, Rhee SG, Williams LT and Zetter BR: Regulation of chemotaxis by the platelet-derived growth factor receptor-β. Nature. 367:474–476. 1994. View Article : Google Scholar : PubMed/NCBI
29	Bornfeldt KE, Raines EW, Nakano T, Graves LM, Krebs EG and Ross R: Insulin-like growth factor-I and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. J Clin Invest. 93:1266–1274. 1994. View Article : Google Scholar : PubMed/NCBI
30	Wells A, Kassis J, Solava J, Turner T and Lauffenburger DA: Growth factor-induced cell motility in tumor invasion. Acta Oncol. 41:124–130. 2002. View Article : Google Scholar : PubMed/NCBI
31	Polk DB: Epidermal growth factor receptor-stimulated intestinal epithelial cell migration requires phospholipase C activity. Gastroenterology. 114:493–502. 1998. View Article : Google Scholar : PubMed/NCBI
32	Wang Y, Wu J and Wang Z: Akt binds to and phosphorylates phospholipase C-gamma1 in response to epidermal growth factor. Mol Biol Cell. 17:2267–2277. 2006. View Article : Google Scholar : PubMed/NCBI
33	Appert-Collin A, Hubert P, Crémel G and Bennasroune A: Role of ErbB receptors in cancer cell migration and invasion. Front Pharmacol. 6:2832015. View Article : Google Scholar : PubMed/NCBI
34	Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T, Seeger JM, Weiss J, Fischer F, Frommolt P, et al: PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res. 69:3256–3261. 2009. View Article : Google Scholar : PubMed/NCBI
35	Bidkhori G, Moeini A and Masoudi-Nejad A: Modeling of tumor progression in NSCLC and intrinsic resistance to TKI in loss of PTEN expression. PLoS One. 7:e480042012. View Article : Google Scholar : PubMed/NCBI
36	Kanda R, Kawahara A, Watari K, Murakami Y, Sonoda K, Maeda M, Fujita H, Kage M, Uramoto H, Costa C, et al: Erlotinib resistance in lung cancer cells mediated by integrin β1/Src/Akt-driven bypass signaling. Cancer Res. 73:6243–6253. 2013. View Article : Google Scholar : PubMed/NCBI
37	Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007. View Article : Google Scholar : PubMed/NCBI
38	Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG and Varmus HE: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2:e172005. View Article : Google Scholar : PubMed/NCBI
39	Wahl M and Carpenter G: Selective phospholipase C activation. BioEssays. 13:107–113. 1991. View Article : Google Scholar : PubMed/NCBI
40	Jang H-J, Suh P-G, Lee YJ, Shin KJ, Cocco L and Chae YC: PLCγ1: Potential arbitrator of cancer progression. Adv Biol Regul. 67:179–189. 2018. View Article : Google Scholar
41	Xie Z, Peng J, Pennypacker SD and Chen Y: Critical role for the catalytic activity of phospholipase C-gamma1 in epidermal growth factor-induced cell migration. Biochem Biophys Res Commun. 399:425–428. 2010. View Article : Google Scholar : PubMed/NCBI
42	Davies G, Martin TA, Ye L, Lewis-Russell JM, Mason MD and Jiang WG: Phospholipase-C gamma-1 (PLCγ-1) is critical in hepatocyte growth factor induced in vitro invasion and migration without affecting the growth of prostate cancer cells. Urol Oncol. 26:386–391. 2008. View Article : Google Scholar : PubMed/NCBI
43	Thomas SM, Coppelli FM, Wells A, Gooding WE, Song J, Kassis J, Drenning SD and Grandis JR: Epidermal growth factor receptor-stimulated activation of phospholipase Cgamma-1 promotes invasion of head and neck squamous cell carcinoma. Cancer Res. 63:5629–5635. 2003.PubMed/NCBI
44	Dai L, Zhuang L and Zhang B, Wang F, Chen X, Xia C and Zhang B: DAG/PKCδ and IP3/Ca²⁺/CaMK IIβ operate in parallel to each other in PLCγ1-driven cell proliferation and migration of human gastric adenocarcinoma cells, through Akt/mTOR/S6 pathway. Int J Mol Sci. 16:28510–28522. 2015. View Article : Google Scholar : PubMed/NCBI
45	Tang W, Zhou Y, Sun D, Dong L, Xia J and Yang B: Oncogenic role of phospholipase C-γ1 in progression of hepatocellular carcinoma. Hepatol Res. 49:559–569. 2019. View Article : Google Scholar : PubMed/NCBI
46	Zhang P, Zhao Y, Zhu X, Sedwick D, Zhang X and Wang Z: Cross-talk between phospho-STAT3 and PLCγ1 plays a critical role in colorectal tumorigenesis. Mol Cancer Res. 9:1418–1428. 2011. View Article : Google Scholar : PubMed/NCBI